All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

May 11th 2023

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

Elacestrant PROs Consistent With Standard of Care Endocrine Therapy in Patients With Metastatic Breast Cancer

May 11th 2023

Elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles, according to patient reported outcomes.

FDA Issues Complete Response Letter to BLA for N-803 in BCG-unresponsive NMIBC in Situ

May 11th 2023

The FDA has issued a complete response letter regarding the biologics license application for N-803 in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.

Blue Light Cystoscopy Enhances Detection of Cancer in the Bladder

May 11th 2023

Saum Ghodoussipour, MD, shares how some facilities in the tri-state region including Rutgers Cancer Institute and Robert Wood Johnson University Hospital, use enhanced blue light technology with an imaging solution that better highlights cancerous tumors in the bladder.

Updated Findings Spur Excitement In nmCRPC, mHSPC, mCRPC

May 11th 2023

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer

May 10th 2023

John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.

Adjuvant Atezolizumab and Bevacizumab Delays Recurrence in Early-Stage HCC

May 10th 2023

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.

Ivosidenib Wins European Approval for IDH1-mutated AML and Cholangiocarcinoma

May 10th 2023

The European Commission has approved ivosidenib tablets in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy, and as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who received at least 1 prior line of systemic therapy.

Extended Administration of Adjuvant Anatrozole Prolongs DFS in Postmenopausal HR+ Breast Cancer

May 10th 2023

Treatment with adjuvant anastrozole over a 10-year period remained tolerable and increased disease-free survival rates in postmenopausal women with hormone receptor–positive breast cancer, according to data from the phase 3 AERAS trial.

Fox Chase Cancer Center Welcomes Dr. Abigail T. Berman

May 10th 2023

Fox Chase Cancer Center is pleased to announce the hiring of Abigail T. Berman, MD, MSCE, as an assistant professor in the Department of Radiation Oncology.

FDA Grants Orphan Drug Status to RAD 301 for Imaging of Pancreatic Ductal Adenocarcinoma

May 10th 2023

The FDA has granted an orphan drug designation to RAD 301 for the imaging of patients with pancreatic ductal adenocarcinoma.

New Research Results Spotlight Rare Molecular Subtypes in NSCLC

May 10th 2023

Although molecularly targeted therapies have transformed the treatment paradigm for NSCLC, the kaleidoscope of genomic alterations that affects subsets of patients is straining the limits of current diagnostic and clinical discovery approaches.

Frontline Avelumab Maintenance Provides Prolonged Survival Benefit in Urothelial Carcinoma

May 10th 2023

Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.

Unpacking the Implications of CAR T-cell Therapy for Patients With Multiple Myeloma

May 9th 2023

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

Short-term QOL Scores Lower in Non-Hispanic Black Patients With Prostate Cancer After Radical Prostatectomy

May 9th 2023

Mara Koelker, MD, discusses the rationale of evaluating racial differences in QOL for patients with prostate cancer and ways to address these short-term disparities in a real-world setting.

Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC

May 9th 2023

John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.

FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer

May 9th 2023

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

International Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby

May 9th 2023

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis

May 9th 2023

Enrollment to the phase 3 MANIFEST-2 trial, which is examining the safety and efficacy of pelabresib plus ruxolitinib vs ruxolitinib alone in patients with JAK inhibitor–naïve myelofibrosis, has completed and topline findings are anticipated by the end of 2023.

Decentralization Efforts Could Engage Community Oncologists

May 9th 2023

As more treatment options enter the oncology landscape, access to these life-changing medicines has become a paramount concern.